With a market capitalization (market cap) of $22.99B — a measure of how much the company is worth — United Therapeutics Corporation ranks #546 among the 2,510 companies tracked, and 67th in Healthcare as of October 3, 2026. Shares trade at $541.70, down 5.19% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $23.08B | +8.87% | $541.70 |
| 2025 | Dec 31, 2025 | $21.2B | +33.79% | $487.25 |
| 2024 | Dec 31, 2024 | $15.84B | +53.29% | $352.84 |
| 2023 | Dec 29, 2023 | $10.33B | -18.86% | $219.89 |
Ranking figure $22.99B as of October 3, 2026.
United Therapeutics Corporation's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $541.70 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $23.08B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 44,300,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, United Therapeutics Corporation (UTHR) is worth $22.99B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, United Therapeutics Corporation’s book equity is about $7.1B. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $22.99B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
United Therapeutics Corporation ranks #546 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #67 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
| 2022 |
|---|
| Dec 30, 2022 |
| $12.74B |
| +23.59% |
| $278.09 |
| 2021 | Dec 31, 2021 | $10.31B | — | $216.08 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #543 | Synchrony Financial SYF | $23.35B | +0.36% |
| #544 | Regions Financial Corporation RF | $23.13B | +0.52% |
| #545 | Veralto Corporation VLTO | $23.08B | +0.08% |
| #547 | Darden Restaurants, Inc. DRI | $22.94B | +1.48% |
| #548 | Casey's General Stores, Inc. CASY | $22.86B | -0.28% |
| #549 | Liberty Media Corporation FWONK | $22.86B | -0.44% |
United Therapeutics Corporation’s ranking market cap of $22.99B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 44,300,000. The historical market-cap series last observed $23.08B on October 2, 2026.
Over the past year, United Therapeutics Corporation’s market cap is up 17.47%, using historical market-cap records rather than today’s share count applied to past prices.
United Therapeutics Corporation (UTHR) shares trade at $541.70, down 5.19% on the day, as of October 3, 2026.
United Therapeutics Corporation trades at a live price-to-earnings (P/E) ratio of 18.0, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.